Go Pro
→ Elon gets it. Do you? (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
$1.28
+1.2%		$1.61
$1.04
▼
$5.50
$53.78M1.241.31 million shs1.14 million shs
BioVie Inc. stock logo
BIVI
BioVie
$1.63
$1.69
$0.82
▼
$3.79
$13.78M0.74505,230 shs216,447 shs
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
$12.11
+0.0%		$11.93
$11.00
▼
$13.10
$50.26M0.04619 shs8,315 shs
ImageneBio, Inc. stock logo
IMA
ImageneBio
$4.87
+0.4%		$5.40
$3.94
▼
$9.10
$55.06M0.718,170 shs1,479 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
+0.79%+18.60%-26.93%-22.96%-42.70%
BioVie Inc. stock logo
BIVI
BioVie
0.00%-5.23%-23.83%-8.43%-11.41%
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
0.00%+2.50%+2.20%+0.80%+8.96%
ImageneBio, Inc. stock logo
IMA
ImageneBio
+0.37%-1.26%-13.38%-18.05%-38.77%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
$1.28
+1.2%		$1.61
$1.04
▼
$5.50
$53.78M1.241.31 million shs1.14 million shs
BioVie Inc. stock logo
BIVI
BioVie
$1.63
$1.69
$0.82
▼
$3.79
$13.78M0.74505,230 shs216,447 shs
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
$12.11
+0.0%		$11.93
$11.00
▼
$13.10
$50.26M0.04619 shs8,315 shs
ImageneBio, Inc. stock logo
IMA
ImageneBio
$4.87
+0.4%		$5.40
$3.94
▼
$9.10
$55.06M0.718,170 shs1,479 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
+0.79%+18.60%-26.93%-22.96%-42.70%
BioVie Inc. stock logo
BIVI
BioVie
0.00%-5.23%-23.83%-8.43%-11.41%
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
0.00%+2.50%+2.20%+0.80%+8.96%
ImageneBio, Inc. stock logo
IMA
ImageneBio
+0.37%-1.26%-13.38%-18.05%-38.77%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
2.25
Hold$12.00841.18% Upside
BioVie Inc. stock logo
BIVI
BioVie
1.00
SellN/AN/A
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
1.00
SellN/AN/A
ImageneBio, Inc. stock logo
IMA
ImageneBio
2.20
Hold$29.00495.73% Upside

Current Analyst Ratings Breakdown

Latest BIVI, ANVS, IMA, and BKHA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/27/2026
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
Roth Capital logo
Roth Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$8.00 ➝ $7.00
8/21/2026
ImageneBio, Inc. stock logo
IMA
ImageneBio
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$28.00
8/21/2026
ImageneBio, Inc. stock logo
IMA
ImageneBio
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$28.00
8/18/2026
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
7/17/2026
BioVie Inc. stock logo
BIVI
BioVie
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
7/9/2026
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
7/7/2026
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
Roth Capital logo
Roth Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$8.00
7/7/2026
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
Roth Capital logo
Roth Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
7/6/2026
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
6/29/2026
ImageneBio, Inc. stock logo
IMA
ImageneBio
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
N/AN/AN/AN/A$0.64 per shareN/A
BioVie Inc. stock logo
BIVI
BioVie
N/AN/AN/AN/A$1.36 per shareN/A
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
N/AN/AN/AN/AN/AN/A
ImageneBio, Inc. stock logo
IMA
ImageneBio
$800K69.06N/AN/A$11.91 per share0.41
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
-$28.85M-$1.79N/AN/AN/AN/A-685.98%-258.77%11/11/2026 (Estimated)
BioVie Inc. stock logo
BIVI
BioVie
-$22.07M-$3.15N/AN/AN/AN/A-126.02%-108.88%11/9/2026 (Estimated)
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
N/AN/AN/AN/AN/AN/AN/AN/AN/A
ImageneBio, Inc. stock logo
IMA
ImageneBio
-$45.35M-$4.58N/AN/AN/AN/A-38.99%-34.84%N/A

Latest BIVI, ANVS, IMA, and BKHA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
-$0.4533-$0.40+$0.0533-$0.40N/AN/A
8/12/2026Q4 2026
BioVie Inc. stock logo
BIVI
BioVie
-$0.52-$0.70-$0.18-$0.70N/AN/A
8/5/2026Q2 2026
ImageneBio, Inc. stock logo
IMA
ImageneBio
-$0.90-$0.63+$0.27-$0.63N/AN/A
7/15/2026Q2 2026
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
N/A$0.02N/A$0.02N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
N/AN/AN/AN/AN/A
BioVie Inc. stock logo
BIVI
BioVie
N/AN/AN/AN/AN/A
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
N/AN/AN/AN/AN/A
ImageneBio, Inc. stock logo
IMA
ImageneBio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
N/A
3.47
3.47
BioVie Inc. stock logo
BIVI
BioVie
N/A
3.59
3.59
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
N/AN/AN/A
ImageneBio, Inc. stock logo
IMA
ImageneBio
N/A
21.47
21.47

Institutional Ownership

CompanyInstitutional Ownership
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
15.83%
BioVie Inc. stock logo
BIVI
BioVie
4.59%
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
N/A
ImageneBio, Inc. stock logo
IMA
ImageneBio
75.00%

Insider Ownership

CompanyInsider Ownership
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
15.92%
BioVie Inc. stock logo
BIVI
BioVie
0.90%
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
N/A
ImageneBio, Inc. stock logo
IMA
ImageneBio
2.22%
CompanyEmployeesShares OutstandingFree FloatOptionable
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
742.68 million35.89 millionOptionable
BioVie Inc. stock logo
BIVI
BioVie
138.45 million8.38 millionNo Data
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
N/A4.15 millionN/AN/A
ImageneBio, Inc. stock logo
IMA
ImageneBio
1811.35 million11.10 millionNot Optionable

Recent News About These Companies

ImageneBio, Inc. (NASDAQ:IMA) Receives $29.00 Average PT from Analysts
September 20, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31033813
ImageneBio, Inc. (NASDAQ:IMA) Receives Consensus Rating of "Hold" from Brokerages
September 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-imagenebio-inc-nasdaq-ima-receives-consensus-rating-of-hold-from-brokerages-2026-09-15/
ImageneBio Corporate Event Calendar | NASDAQ:IMA
September 13, 2026  |  benzinga.comhttps://www.benzinga.com/quote/IMA/events
ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York
September 8, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/imagenebio-to-participate-in-h-c-wainwright-28th-annual-global-investment-conference-in-new-york-1036530172
ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York
September 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/08/3358135/0/en/imagenebio-to-participate-in-h-c-wainwright-28th-annual-global-investment-conference-in-new-york.html
ImageneBio, Inc. (NASDAQ:IMA) Sees Significant Decline in Short Interest
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/options-imagenebio-inc-nasdaq-ima-sees-significant-decline-in-short-interest-2026-08-26/
Trails Edge Capital Partners LP Invests $1.66 Billion in ImageneBio, Inc. $IMA
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-trails-edge-capital-partners-lp-invests-166-billion-in-imagenebio-inc-ima-2026-08-26/
Cable Car Capital LP Makes New Investment in ImageneBio, Inc. $IMA
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-cable-car-capital-lp-makes-new-investment-in-imagenebio-inc-ima-2026-08-26/
What is HC Wainwright's Estimate for ImageneBio Q3 Earnings?
August 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-what-is-hc-wainwrights-estimate-for-imagenebio-q3-earnings-2026-08-25/
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 17, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/imagenebio-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-1036468494
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/17/3346489/0/en/imagenebio-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
ImageneBio, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026
August 6, 2026  |  zonebourse.comZ
ImageneBio Reports Second Quarter 2026 Financial Results
August 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/05/3339263/0/en/imagenebio-reports-second-quarter-2026-financial-results.html
ImageneBio Strengthens Leadership with New CFO Appointment
July 23, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/imagenebio-strengthens-leadership-with-new-cfo-appointment?utm_source=marketbeat.com&utm_medium=referral
ImageneBio Stock Short Interest Report | NASDAQ:IMA | Benzinga
July 7, 2026  |  benzinga.comhttps://www.benzinga.com/quote/IMA/short-interest
ImageneBio Appoints Matt Robbins as General Counsel
July 7, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/imagenebio-appoints-matt-robbins-as-general-counsel-1036302734
ImageneBio Appoints Matt Robbins as General Counsel
July 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/07/3323019/0/en/imagenebio-appoints-matt-robbins-as-general-counsel.html
ImageneBio, Inc. Common Stock
June 27, 2026  |  fxempire.comF
ImageneBio, Inc. Common Stock (IMA) SEC Filings
June 25, 2026  |  nasdaq.comhttps://www.nasdaq.com/market-activity/stocks/ima/sec-filings
ImageneBio Shareholders Back Directors and Governance Proposals
June 17, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/imagenebio-shareholders-back-directors-and-governance-proposals?utm_source=marketbeat.com&utm_medium=referral
ImageneBio to Participate in 2026 Jefferies Global Healthcare Conference in New York
May 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/27/3302402/0/en/imagenebio-to-participate-in-2026-jefferies-global-healthcare-conference-in-new-york.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Broadcom logo displayed on a computer chip embedded in a circuit board with glowing blue connections.
The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
By Leo Miller | September 3, 2026
Adobe logo displayed on a wall behind an office desk with a laptop, notebook, and pens.
Analysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed Earnings
By Dan Schmidt | September 14, 2026
Illustration of a server data center with an upward-trending chart line overlaid against a city skyline at sunset.
Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For
By Thomas Hughes | September 8, 2026
Dutch Bros drive-thru location with windmill logo signage and cars in line at dusk.
Dutch Bros Sell-Off Creates a Growth Opportunity
By Peter Frank | September 1, 2026
D-Wave logo illuminated on a lit panel, flanked by a quantum computing rig and server racks.
The Bull Case for D-Wave After a Disappointing Earnings Season
By Nathan Reiff | August 25, 2026
Annovis Bio stock logo

Annovis Bio NYSE:ANVS

$1.27 +0.02 (+1.19%)
Closing price 09/23/2026 03:59 PM Eastern
Extended Trading
$1.29 +0.02 (+1.18%)
As of 07:42 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

BioVie stock logo

BioVie NASDAQ:BIVI

$1.63 0.00 (0.00%)
Closing price 09/23/2026 04:00 PM Eastern
Extended Trading
$1.62 -0.01 (-0.37%)
As of 07:25 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

Black Hawk Acquisition stock logo

Black Hawk Acquisition NASDAQ:BKHA

$12.10 +0.01 (+0.04%)
As of 09/23/2026 03:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Black Hawk Acquisition Corporation focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2023 and is based in Danville, California.

ImageneBio stock logo

ImageneBio NASDAQ:IMA

$4.87 +0.02 (+0.37%)
Closing price 09/23/2026 03:58 PM Eastern
Extended Trading
$4.86 -0.01 (-0.27%)
As of 09/23/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas